Adacel® Vaccine Description 2023
Sanofi Pasteur Limited Adacel® vaccine (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine, Adsorbed) contains noninfectious tetanus, diphtheria, and pertussis proteins, aluminum phosphate, 2-phenoxyethanol, and residual amounts of formaldehyde and glutaraldehyde. Adacel vaccine does not contain preservatives.
Adacel is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. Adacel is U.S. Food and Drug Administration (FDA) approved (STN: BL 125111/904 ) for use in persons 10 through 64 years of age and immunization during the third trimester of pregnancy to prevent pertussis in infants younger than two months of age.
The JAMA Pediatrics published an Original Investigation on February 6, 2023: US Infant Pertussis Incidence Trends Before and After Implementation of the Maternal Tetanus, Diphtheria, and Pertussis Vaccine, that concluded following maternal Tdap vaccine introduction, a sustained decrease in pertussis incidence was observed among infants younger than two months, narrowing the incidence gap with infants aged six months to less than 12 months. These findings suggest that maternal Tdap vaccination is associated with a reduction in pertussis burden in the target age group (<2 months) and that further increases in coverage may be related to additional decreases in infant disease.
“Everyone pregnant should feel confident knowing that the Tdap vaccine is safe and effective,” said Linda Eckert, M.D., American College of Obstetricians and Gynecologists’ liaison to the CDC’s Advisory Committee on Immunization Practices in an AAP press release on February 6, 2023. “Knowing that Tdap vaccination during pregnancy protects nine in 10 babies from being hospitalized with whooping cough, I strongly recommend this vaccine to all my pregnant patients for their peace of mind and their family’s health and well-being.”
Adacel Vaccine Indication
Adacel (Tdap) is indicated for active booster immunization to prevent tetanus, diphtheria, and pertussis in people at least ten through 64. Adacel given during the third trimester of pregnancy, helps the pregnant woman create antibodies against the bacteria that cause whooping cough (pertussis) that are passed to her baby before birth. These antibodies help protect the baby against whooping cough during the first few months of life.
Adacel Vaccine Dosage
The Adacel vaccine is administered as an intramuscular injection into the muscle of the upper arm and approved as a single dose in individuals ten through age. 64 Therefore, most people in this age group require only one Tdap shot for protection against these diseases. In addition, Adacel is available in a syringe made without natural rubber latex, which may help reduce risk to patients with an allergy.
Adacel Vaccine News 2019 - 2023
February 6, 2023 - The AAP News published: Study: Tdap vaccination during pregnancy linked to lower pertussis rates in newborns.
January 10, 2023 - The U.S. FDA announced Adacel was approved for immunization during the third trimester of pregnancy to prevent pertussis in infants younger than two months.
January 15, 2019 - 1st Tdap Vaccine Approved for a 2nd Dose.
January 11, 2019 - The U.S. Food and Drug Administration has approved the expanded use of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria, and pertussis. It is now the first Tdap vaccine in the U.S. approved for a repeat dose in people 10 through 64 years.
Adacel Vaccine Clinical Trials
Adacel has been involved in over 19 clinical studies.